🟢 Context Therapeutics is trading 6.5% up in after-hours trading with no clear catalyst identified

Context Therapeutics is trading at $0.32, up 6.5%, after a sharp after-hours reversal following several consecutive daily declines.

• Shares closed the September 30 regular session at $0.30.
• No clear company-specific catalyst was identified, and the available market context is mixed.
• The latest listed company press release is the September 9 announcement that the first patient was dosed in the CT-202 Phase 1 trial; the release page lists no September 30 announcement.